Giovanni Battista Migliori, Simon Tiberi, Alimuddin Zumla, Eskild Petersen et al.
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health staff with an updated and easy-to-consult document arising from consensus of Glob...
Borisov Se, Edvardas Danila, Andrei Maryandyshev, Margareth Pretti Dalcolmo et al.
The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events. The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculo...
Mohammad Javad Nasiri, Moein Zangiabadian, Erfan Arabpour, S. Amini et al.
INTRODUCTION: Multidrug-resistant tuberculosis (MDR-TB) is a life-threatening condition needing long poly-chemotherapy regimens. As no systematic reviews/meta-analysis is available to comprehensively evaluate the role of delamanid (DLM), we evaluated its effectiveness and safety. METHODS: We reviewe...
Onno W. Akkerman, Alena Aleksa, Jan‐Willem C. Alffenaar, Nada Hassan Al-Marzouqi et al.
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to...
Seif Al Abri, Tereza Kasaeva, Giovanni Battista Migliori, Delia Goletti et al.
AIM: The purpose of this viewpoint is to summarize the advantages and constraints of the tools and strategies available for reducing the annual incidence of tuberculosis (TB) by implementing the World Health Organization (WHO) End TB Strategy and the linked WHO TB Elimination Framework, with special...
Giovanni Sotgiu, Simon Tiberi, Rosella Centis, Lia D’Ambrosio et al.
In spite of the recent introduction of two new drugs (delamanid and bedaquiline) and a few repurposed compounds to treat multidrug-resistant and extensively drug-resistant tuberculosis (MDR- and XDR-TB), clinicians are facing increasing problems in designing effective regimens in severe cases. Recen...
S Koirala, Borisov Se, Edvardas Danila, Andrei Mariandyshev et al.
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB pa...
José A. Caminero, Alberto L. García‐Basteiro, Adrián Rendón, Alberto Piubello et al.
The World Health Organization (WHO) recently launched the consolidated guidelines on drug-resistant tuberculosis (DR-TB) treatment [1]. They include a new drug classification to manage rifampicin-resistant (RR) and multidrug-resistant (MDR)-TB, while proposing either a shorter regimen (including inj...
Giovanni Battista Migliori, Pei Min Thong, Jan‐Willem C. Alffenaar, Justin T. Denholm et al.
The objective of this study was to describe country-specific lockdown measures and tuberculosis indicators collected during the first year of the COVID-19 pandemic. Data on lockdown/social restrictions (compulsory face masks and hand hygiene; international and local travel restrictions; restrictions...
Emanuele Pontali, Dina Visca, Rosella Centis, Lia D’Ambrosio et al.
PURPOSE OF REVIEW: Multidrug-resistant (MDR) tuberculosis (TB) and extensively drug-resistant (XDR)-TB epidemics are key obstacles towards TB control and elimination. RECENT FINDINGS: Diagnosis of MDR/XDR-TB is difficult and requires several weeks. New diagnostic tools are being tested and proposed ...
Eskild Petersen, Seif Al-Abri, Jeremiah Chakaya, Delia Goletti et al.
The World Health Organization (WHO) and STOP TB Partnership theme for World TB Day 24th March, 2022 is “Invest to End TB. Save Lives” (WHO, 2022a). Global political and scientific attention continues to be focussed on the Coronavirus disease (COVID-19) pandemic. There have been over 416 million case...
Marcela Muñóz-Torrico, J.A. Caminero Luna, Giovanni Battista Migliori, Lia D’Ambrosio et al.
Diabetes mellitus (DM) is a well-known risk factor for tuberculosis (TB). However, it is not known to what extent DM affects the outcome in patients with multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) treated with second-line anti-TB drugs. The objective of this study was to...
Simon Tiberi, Giovanni Battista Migliori, Jeremiah Chakaya, Tereza Kaesava et al.
World TB Day falls on March 24th each year, and it commemorates the day in 1882 when Dr Robert Koch announced that he had discovered the microbial cause of tuberculosis, Mycobacterium tuberculosis (WHO, 2020aWHO World tuberculosis day.2020https://www.who.int/news-room/events/detail/2020/03/24/defaul...
Giovanni Sotgiu, Giovanni Battista Migliori
In May, 2016, WHO launched new guidelines for the management of multidrug-resistant tuberculosis,1WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. World Health Organization, Geneva2016http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/resources/enGoogle Scholar inc...
Denise Rossato Silva, Rosella Centis, Lia D’Ambrosio, Fernanda Carvalho de Queiroz Mello et al.